Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion

Furugaki, Koh; Mochizuki, Marie; Kohno, Mirei; Shu, Sei; Harada, Naoki; Yoshimura, Yasushi

doi:10.1186/s12885-019-5527-2

BMC Cancer

Table 1 37 lung cancer cell lines

From: Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion

N	Cell line	Histology	Driver gene mutation	Supplier	Catalogue number	Culture medium
1	NCI-H2228	AD	EML4-ALK¹	ATCC	CRL-5935	10%FBS-RPMI1640
2	SNU-2535	NS	EML4-ALK, G1269A²	KCLB	02535	10%FBS-RPMI1640
3	SNU-2292	AD	EML4-ALK³	KCLB	02292	10%FBS-RPMI1640
4	HCC827	AD	EGFR E746_A750 DL¹	ATCC	CRL-2868	10%FBS-RPMI1640
5	PC-9	AD	EGFR E746_A750 DL¹	IBL	37,012	10%FBS-RPMI1640
6	B901L	AD	EGFR E746_A750 DL¹	RIKEN	RCB3530	10%FBS-RPMI1640
7	HCC4006	AD	EGFR L747_E749 DL, A750P⁴	ATCC	CRL-2871	10%FBS-RPMI1640
8	HCC2935	AD	EGFR E746_T751 DL, S752I⁴	ATCC	CRL-2869	10%FBS-RPMI1640
9	PC-3	AD	EGFR L747_A750 DL¹	HSRRB	JCRB0077	10%FBS-MEM
10	NCI-H1650	AD	EGFR E746_A750 DL¹	ATCC	CRL-5883	10%FBS-RPMI1640
11	II-18	AD	EGFR L858R¹	RIKEN	RCB2093	10%FBS-RPMI1640
12	NCI-H1975	AD	EGFR L858R, T790M¹	ATCC	CRL-5908	10%FBS-RPMI1640
13	NCI-H820	AD	EGFR E746_T751 DL, T790M⁵	ATCC	HTB-181	10%FBS-RPMI1640
14	Calu-1	SQ	KRAS G12C¹	ATCC	HTB-54	10%FBS-McCoy’s 5A
15	NCI-H358	AD	KRAS G12C¹	ATCC	CRL-5807	10%FBS-RPMI1640
16	HOP-62	AD	KRAS G12C¹	NCI	502,467	10%FBS-RPMI1640
17	NCI-H2122	AD	KRAS G12C¹	ATCC	CRL-5985	10%FBS-RPMI1640
18	Calu-6	AC	KRAS Q61K¹	ATCC	HTB-56	10%FBS-MEM
19	NCI-H460	LC	KRAS Q61H, PIK3CA E545K¹	ATCC	HTB-177	10%FBS-RPMI1640
20	NCI-H596	AS	PIK3CA E545K¹	ATCC	HTB-178	10%FBS-RPMI1640
21	NCI-H1781	AD	ERBB2 G776VC¹	ATCC	CRL-5894	10%FBS-RPMI1640
22	NCI-H1755	AD	BRAF G469A¹	ATCC	CRL-5892	10%FBS-RPMI1640
23	LC-2/ad	AD	CCDC6-RET⁶	RIKEN	RCB0440	15%FBS-HAMF12
24	HCC78	AD	SLC34A2-ROS1¹	DSMZ	ACC563	10%FBS-RPMI1640
25	NCI-H2347	AD	NRAS Q61R¹	ATCC	CRL-5942	10%FBS-RPMI1640
26	NCI-H1993	AD	MET amplification¹	ATCC	CRL-5909	10%FBS-RPMI1640
27	NCI-H1568	AD	ND¹	ATCC	CRL-5876	10%FBS-RPMI1640
28	NCI-H522	AD	ND¹	ATCC	CRL-5810	10%FBS-RPMI1640
29	NCI-H838	AD	ND¹	ATCC	CRL-5844	10%FBS-RPMI1640
30	A529L	AS	ND¹	RIKEN	RCB2817	10%FBS-RPMI1640
31	NCI-H1703	AD	ND¹	ATCC	CRL-5889	10%FBS-RPMI1640
32	NCI-H520	SQ	ND¹	ATCC	HTB-182	10%FBS-RPMI1640
33	NCI-H2170	SQ	ND¹	ATCC	CRL-5928	10%FBS-RPMI1640
34	NCI-H226	SQ	ND¹	ATCC	CRL-5826	10%FBS-RPMI1640
35	SK-MES-1	SQ	ND¹	ATCC	HTB-58	10%FBS-MEM
36	NCI-H1915	LC	ND¹	ATCC	CRL-5904	10%FBS-RPMI1640
37	NCI-H292	MC	ND¹	ATCC	CRL-1848	10%FBS-RPMI1640

AD Adenocarcinoma, NS Non-small cell carcinoma, SQ Squamous carcinoma, AC Anaplastic carcinoma, LC Large cell carcinoma, AS Adenosquamous carcinoma, MC Mucoepidermoid carcinoma, DL Deletion, ND Not detected. Mutations were referred from ¹ COSMIC cell database, ² Yoshimura Y. et al., ³ Additional file 5: Figure S1a,⁴ ATCC’s datasheet, ⁵ Shimamura T. et al., ⁶ Matsubara D. et al.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com